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Abstract
DNA cytosine methylation is an important epigenetic mechanism that is involved in transcriptional silencing of
developmental genes. Several molecular pathways have been described that interfere with Pol II initiation, but at individual
genes the molecular mechanism of repression remains uncertain. Here, we study the molecular mechanism of
transcriptional regulation at Hox genes in dependence of the epigenetic regulator Lsh that controls CpG methylation at
selected Hox genes. Wild type cells show a nucleosomal deprived region around the transcriptional start site at methylated
Hox genes and mediate gene silencing via Pol II stalling. Hypomethylation in Lsh2/2 cells is associated with efficient
transcriptional elongation and splicing, in part mediated by the chromodomain protein Chd1. Dynamic modulation of DNA
methylation in Lsh2/2 and wild type cells demonstrates that catalytically active DNA methyltransferase activity is required
for Pol II stalling. Taken together, the data suggests that DNA methylation can be compatible with Pol II binding at selected
genes and Pol II stalling can act as alternate mechanism to explain transcriptional silencing associated with DNA
methylation.
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Introduction
DNA cytosine methylation is one of the major mechanisms
involved in epigenetics since the pattern of DNA methylation is
faithfully inherited by the next cell generation [1]. DNA cytosine
methylation mediates transcriptional silencing and is crucial for
the process of X inactivation, genomic imprinting and the control
of developmental gene expression [2,3]. Since DNA cytosine
methylation is tightly linked with tumor suppressor gene silencing
in cancer cells, it is also thought to play a role in tumorigenesis.
The prevalent cytosine methylation in mammals occurs in the
CpG context in differentiated cells, however, a recent study
reports DNA methylation in a non-CpG context in human
embryonal stem cells, possibly a unique feature associated with
pluripotency [4].
CpG methylation shows an inverse relationship with transcript
levels, and multiple mechanisms have been implicated to explain
gene silencing in dependence of DNA methylation [1]. Although
an effect of DNA methylation at the elongation phase of
transcription on reporter transgenes has been reported [5,6], most
molecular mechanisms proposed to act on endogenous genes focus
on the initiation phase of transcription. For example, DNA
methylation can prevent binding of some transcriptional activators
to their specific DNA sequences; furthermore, methyl-DNA
binding proteins can recruit repressor complexes thus interfering
with transcriptional initiation; moreover, DNA methyltransferases
can interact with histone deacetylases rendering histones hypoa-
cetylated. Histone acetylation in turn is part of the chromatin
context that can facilitate the assembly of the Pol II and general
transcription factor complex thus promoting transcriptional
initiation [7]. In addition, a recent study demonstrated nucleoso-
mal positioning at the transcriptional start site of the human
MLH1 promoter in dependence of DNA methylation thus
precluding Pol II binding [8]. These diverse mechanisms can
interfere with transcriptional initiation, and for this reason, DNA
methylation studies are frequently focused on promoter regions.
CpG methylation pattern are established and maintained by a
family of DNA methyltransferases (Dnmt): Dnmt3a and Dnmt3b
can act as de novo methyltransferases whereas Dnmt1 primarily
maintains methylation pattern at the replication fork [1,9]. In
addition, other factors have been identified that support the
establishment of DNA methylation pattern during development
[9], for example NP95 enhances Dnmt1 association to hemi-
methylated DNA, and the SNF2 chromatin remodeling family
members ATRX controls methylation at ribosomal DNA and some
satellite sequences. Lsh (Lymphoid specific helicase, also known as
Pasg, HELLS, SMARCA6) is a SNF2 family member that controls
DNA methylation during mammalian development. Likewise, the
close A. thaliana homologue DDM1 (decrease in DNA methylation
1) affects DNAmethylationin plants[10,11,12,13].Lsh caninteract
with Dnmts, and part of its effect on DNA methylation may be
explained by enhanced association of Dnmts with genomic targets
in the presence of Lsh [14,15,16,17]. Among the genomic targets of
Lsh are repeat elements, such as minor and major satellite
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elements [10,13,18,19]. In addition, several specific genomic sites
were identified as targets for Lsh, such as p57, Pu.1, and
pluripotency genes, Oct4 or Nanog [14,17,20,21].
Previously, we reported that Lsh regulates the DNA methylation
pattern and gene expression level of HoxA6 and HoxA7 genes in
embryonic tissues and embryonal fibroblast lines [16]. Hox
proteins are important developmental regulators that are con-
trolled by tri-thorax group proteins, such as MLL (mixed
lymphocyte leukemia), and by polycomb proteins [22]. Whereas
MLL catalyzes methylation of histone H3 lysine 4 (H3K4me), the
polycomb repressor complexes mediate H3K27 methylation and
H2A ubiquitylation. In addition, a functional link between Dnmts
and polycomb proteins has been identified [23], and it is now well
documented that DNA methylation occurs during normal cellular
differentiation at Hox gene clusters [24,25,26,27]. Although DNA
methylation is associated with Hox gene transcript levels, the
mechanism of gene silencing remains uncertain, since polycomb
mediated repression shows widespread Pol II stalling in Drosophila
[28], but DNA methylation is thought to prevent Pol II binding
and initiation [1].
To address the molecular mechanism of Hox gene silencing in
dependence of Lsh and DNA methylation we examined
nucleosomal positioning, RNA Pol II binding, RNA splicing and
diverse histone modifications comparing wild type cells to
hypomethylated Lsh2/2 cells, or dynamically regulating DNA
methylation levels in WT and Lsh2/2 cells. Despite substantial
differences in DNA methylation at HoxC genes we found similar
nucleosomal positioning and abundant RNA Pol II binding in
both Lsh2/2 and wild type cells. Whereas methylated Hox genes
in wild type cells show Pol II stalling, hypomethylated Hox genes
have successful transcriptional elongation and efficient splicing.
Moreover, dynamic modulation of DNA methylation in WT and
Lsh2/2 cells demonstrates a role for catalytically active Dnmt3b.
Thus, our data suggests Pol II stalling as an alternate molecular
pathway to induce transcriptional silencing at methylated genes.
Results
To study the molecular mechanisms of Lsh mediated gene
silencing, we first examined Hox gene expression in murine
embryonal fibroblast (MEF) cell lines derived from Lsh2/2 and
wild type (WT) embryos by RT-PCR analysis and Real-time PCR
analysis (Fig. 1A). Similarly to our previous report on HoxA6 and
HoxA7 genes, HoxC6 and HoxC8 mRNA expression was evident
in Lsh2/2 MEFs and repressed in WT MEFs [16]. Using
chromatin immunoprecipitation (ChIP) analysis and specific
antibodies against Lsh, we found that Lsh was associated with
upstream and downstream regions of HoxC6, HoxC8 and HoxA6
genes (Fig. S1A,B,C). This suggests that Lsh, at least in part, acts
directly on Hox gene expression. Similarly to our previous findings
at HoxA6 and HoxA7 genes [16], we detected profound DNA
methylation differences at the promoter regions of HoxC6 and C8
genes using methylation sensitive restriction enzymes followed by
PCR analysis (Fig. S2A,B) and MeDIP analysis (Fig. S2C,D). To
generate a precise CpG methylation map, bisulphite sequencing
analysis was performed evaluating a region of about 2000 bp
upstream and 1000 bp downstream of the TSS at either HoxC6 or
HoxC8 genes (Fig. 1B,C). The overall DNA methylation levels
varied greatly between WT cells and Lsh2/2 samples. In
particular, the methylation level at the CpG islands in close
proximitytotheTSSwasreduced atHoxC6(10fold)and HoxC8(7
fold) genes in Lsh2/2 MEFs. This demonstrates that Lsh regulates
DNA methylation at HoxC6 and HoxC8 genes in WT MEFs.
To address the question whether Lsh controls HoxC6 and
HoxC8 genes during embryonic development [29,30], we exam-
ined HoxC6 and HoxC8 gene expression by RT-PCR analysis in
diverse tissues derived from day13.5 embryos. Forelimb, hindlimb
and lung tissue showed signs of de-repression at HoxC6 and HoxC8
genes in the absence of Lsh, but HoxC8 expression in liver tissue
was not affected by Lsh (Fig. 1D) suggesting that depletion of Lsh
cannot re-activate specific Hox genes in every tissue, as has been
previously described [16]. Bisulphite sequencing showed reduced
DNA methylation in Lsh2/2 hindlimb tissue compared to WT at
HoxC6 and HoxC8 genes, similarly to the results in MEFs(Fig. 1E).
Consistent with transcript levels, DNA methylation in liver tissue
wasnot significantly changed comparingWTandLsh2/2samples.
Importantly, DNA hypomethylation was found at sites of active
transcription, (HoxC6 in liver or Lsh2/2 hindlimb), whereas DNA
methylation was present at repressed sites (HoxC8 liver or WT
hindlimb), supporting the idea that DNA methylation is closely
associated with gene silencing. Overall, Lsh is associated with DNA
methylation and is involved in gene silencing at HoxC6 and HoxC8
genesinembryoderived celllinesandinembryonal tissue at specific
developmental stages.
Phased nucleosomal positioning at TSS or enhancer elements is
associated with active transcription, and regular nucleosomal
pattern have been found at Hox clusters [31,32,33,34]. Further-
more, Lsh is a homologue of SNF2 factors and may affect
nucleosomal positioning at HoxC genes; although Lsh has not
been demonstrated, as yet, to posses nucleosomal remodeling
activity. To examine nucleosomal positioning at Hox genes, we
performed a MNase protection assay [33] comparing mononu-
cleosomes prepared from wild type or Lsh2/2 samples by tiling
PCR analysis (Fig. 2A). As shown in Fig. 2B,C, a similar pattern of
MNase sensitivity around the promoter regions of HoxC6 and
HoxC8 was observed comparing WT and Lsh2/2 samples (for
HoxA6 see Fig. S3A). The pattern suggested a fixed +1
nucleosome with a less pronounced 21 nucleosome and revealed
a MNase unprotected region around the TSS. In further support,
mononucleosomal DNA was subjected to MeDIP analysis to
enrich for methylated DNA around the TSS of WT cells. Wild
types samples revealed a MNase unprotected region around the
TSS (Fig. 2D). Taken together, the results suggested that DNA
hyper- or hypomethylation in WT or Lsh2/2 cells had no
detectable effect on nucleosomal positioning at those genes and
wild type samples revealed a MNase unprotected region around
the TSS similar to that in Lsh2/2 samples.
Nucleosomal deprived regions can be associated with active
promoter regions and engaged RNA Pol II [33]. Thus, we tested
the idea whether the MNase unprotected region around the TSS
of Hox genes in WT or Lsh2/2 samples could be linked to Pol II
binding. First, we confirmed the position of the major TSS sites at
either HoxC6 and HoxC8 genes by using 59RACE and site
specific RT-PCR analysis (Fig. S4). Then, ChIPs analysis was
performed using specific antibodies raised against the heptapeptide
repeat of the carboxyterminal domain (CTD) of Pol II. Chromatin
samples derived from Lsh2/2 MEFs showed enrichment of Pol II
at the TSS of HoxC6 and HoxC8 genes (Fig. 3A, and for HoxA6
Fig. S3B). Likewise, WT samples showed a peak of unpho-
sphorylated Pol II binding at TSS consistent with the hypothesis
that Pol II binding may interfere with nucleosomal occupancy and
may determine phasing of the +1 nucleosome [33]. These findings
suggest that CpG island methylation at HoxC6 and HoxC8 genes
does not inevitably hinder Pol II binding. Moreover, repression of
HoxC6 and HoxC8 transcription was not simply caused by a lack
of Pol II binding but by a molecular mechanism following Pol II
engagement.
Lsh Mediated Pol II Stalling
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occupancy at promoter regions of genes that were thought to be
transcriptional silent [35,36]. At those promoters a Pol II initiation
complex is assembled but the elongation process is repressed
leading to Pol II stalling. To test for Pol II stalling in
transcriptional repressed WT MEFs ChIPs analysis was performed
for detection of Ser5 phosphorylated Pol II which is associated
with transcription initiation and early elongation or promoter
clearance [37]. The binding of Ser5 Pol II at the promoter region
was compared to the binding at the gene body to assess successful
Pol II elongation. Whereas WT and Lsh2/2 samples showed
binding of Ser5 Pol II at the TSS of HoxC6 and HoxC8 (Fig. 3B
and for HoxA6 Fig. S3B), only Lsh2/2 samples were enriched for
Ser5 Pol II at the gene body consistent with the hypothesis of
successful elongation in the absence of Lsh. The ratio of Pol II
binding at the TSS over the gene body (downstream) determines
the Pol II stalling index [38]. The Pol II stalling index was
comparatively high in WT samples (about 16 to 25) and low in
Lsh2/2 samples (2 to 3 fold)(Fig. 3C). In further support, the ratio
of Ser5 Pol II binding to a 59region over a 39 region at the first
exon at either HoxC6 or HoxC8 genes was 4 to 6 fold higher in
WT samples compared to Lsh2/2 samples (Fig. 3C and for
HoxA6 Fig. S3C). Furthermore, to address the question whether
Pol II stalling could be detected in WT embryonic tissue, ChIPs
analysis for detection of Ser 5 Pol II was performed for hindlimb
and liver tissue comparing WT and Lsh2/2 embryos. Wild type
hindlimb samples showed exclusive enrichment for Ser5 Pol II
binding at the TSS region, but not at the gene body, suggesting
Pol II stalling. In contrast, Lsh2/2 hindlimb samples showed a
similar Pol II enrichment at the TSS region and the gene body
(Fig. 3D) indicating successful Pol II elongation. Liver samples
revealed no significant differences between WT and Lsh2/2
samples. In particular, HoxC6 showed a high level of Ser5 Pol II
engagement at TSS and gene body, whereas HoxC8 had only
enrichment at the TSS site consistent with the observation of
transcript levels in those tissues. Taken together, a Pol II initiation
complex can engage in Lsh2/2 and WT cells, at hyper or
hypomethylated TSS regions; however, Pol II binding at the gene
body is only associated with hypomethylated HoxC6 and HoxC8
genes. Thus, the observation of Pol II stalling versus Pol II
Figure 1. DNA methylation at silenced HoxC6 and HoxC8 genes. (A) RT-PCR analysis for detection of indicated Hox genes using total RNA
derived from Lsh+/+ and Lsh2/2 MEFs (Top panel) and Real-time PCR analysis (Bottom panel). Primers were employed in exon1 and exon2 thus
detecting spliced transcripts. Gene expression levels were normalized against the housekeeping gene Gapdh and are represented as fold increase in
Lsh2/2 cells compared to Lsh+/+. Error bars represent the mean standard deviation of three independent experiments. (B, C) Genomic DNA derived
from Lsh+/+ and Lsh2/2 MEFs was examined by bisulphite sequencing at regions 2000 bp upstream and 1000 bp downstream of TSS at the HoxC6
(B) or HoxC8 (C) genes. Fifty of 53 CpG sites at the HoxC6 gene and 76 of 80 CpG sites at the HoxC8 gene were analyzed. Methylated CpGs are
presented by black circles and unmethylated sites by open circles. The position of CpG sites is indicated by red lines in the graph and the light blue
color indicates CpG islands according to http://www.urogene.org/methprimer/ (D) RT-PCR analysis for detection of indicated Hox genes in different
tissues from Lsh+/+ and Lsh2/2 embryos d13.5. (E). Genomic DNA derived from indicated tissues from Lsh+/+ and Lsh2/2 embryos d13.5 was
examined by bisulphite sequencing at regions indicated.
doi:10.1371/journal.pone.0009163.g001
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methylation at HoxC6 and HoxC8 genes.
To support further the notion of Pol II stalling versus
elongation, histone modifications that are hallmarks of RNA Pol
II elongation and enriched at the gene body were assessed
[35,39,40]. Histone 3 lysine 36 trimethylation (H3K36me3) and
H3K79 dimethylation (H3K79me2) are present at fairly equal
levels in cellular extracts of Lsh2/2 and WT cells (Fig. S5). Both
H3K36me3 and H3K79me2 showed enrichment at the gene body
of HoxC6 and HoxC8 genes in Lsh2/2 cells compared to WT
cells (Fig. 4A, B, C). Furthermore, Ser2 Pol II enrichment at the 39
end, another hallmark of successful transcriptional elongation [36]
was increased at HoxC6 and HoxC8 genes in Lsh2/2 cells
compared to WT samples (Fig. 4D). Taken together, the change in
histone modifications and Ser2 Pol II further supported the
observation of Pol II stalling at HoxC6 and HoxC8 genes in WT
cells and successful Pol II elongation and transcription in Lsh2/2
MEFs.
To reveal part of the molecular mechanism that is involved in
transcriptional elongation in Lsh2/2 cells, we examined H3K4
trimethylation (H3K4me3) and binding of Chd1. The chromodo-
main protein Chd1 recognizes the lysine methyl mark and has
been shown to promote transcriptional elongation [41,42].
Previously, we reported increased H3K4 methylation levels at
hypomethylated repeat elements in Lsh2/2 cells and 5-Azacyti-
dine treated WT cells [43]. As shown in Fig. 4E, Lsh2/2 samples
had increased of H3K4me3 at HoxC6 and HoxC8 genes, whereas
WT samples showed very little enrichment. In addition, Chd1
bound more efficiently at HoxC6 and HoxC8 genes in Lsh2/2
samples compared to WT samples (Fig. 4F). The difference in
Chd1 association may be due to HoxC specific differences in
H3K4me3 levels or due to slightly higher overall Chd1 protein
levels in Lsh2/2 cells (Fig. S5). To test whether Chd1 is
functionally involved in HoxC6 and HoxC8 gene expression,
Lsh2/2 cells were specifically depleted of Chd1 mRNA (Fig. S6B)
and Chd1 protein (Fig. 4G) using small interfering RNA (siRNA).
Within 48 hrs of siChd1 RNA treatment, HoxC6 and HoxC8
mRNA showed a significant suppression (46% and 67%
respectively) compared to control siRNA treated Lsh2/2 cells
(Fig. 4H). This suggests that Chd1 plays a functional role in the
transcription of HoxC6 and HoxC8 genes in Lsh2/2 cells.
To delineate further the role of Chd1 in transcription, we
examined the maturation of pre-mRNA to spliced RNA since
Chd1 associates with elongation factors as well as splicing
components, and consequently, depletion of Chd1 impairs the
splicing efficiency [41,42]. Primers were designed to detect
transcripts at HoxC6 and HoxC8 genes: for detection of ‘total’
transcripts (at the first exon,a), for pre-mRNA (at the exon/intron
boundary,b), or for spliced RNA (c, spanning both exons)(Fig. 5A).
The ratio of total transcripts to spliced RNA (a/c) and pre-mRNA
to spliced RNA (b/c) was lower in Lsh2/2 samples compared to
WT samples suggesting that Lsh2/2 cells were relatively more
efficient in splicing than WT cells (Fig. 5B). Nuclear RNA samples
derived from WT cells showed some evidence of transcripts close
to the TSS (site a) and transcripts of pre-mRNA (site b) but barely
detectable spliced transcripts (site c) in contrast to Lsh2/2
samples (Fig. 5C). To rule out effects of RNA long-term stability
and to quantify transcription rates, a nuclear run-on assay was
performed using Br-UTP labeling for detection of nascent RNA
[44]. Efficient immunoprecipitation was detected in cells that had
been labeled with Br-UTP indicating the specificity of the assay
(Fig. S6A,B). Using nascent transcripts, the ratio of pre-mRNA to
Figure 2. MNase protected sites are similar at methylated and hypomethylated Hox genes. (A) Diagram depicting the procedure for the
MNase assay and the PCR amplicons used for the detection of Hox genes. The chromatin derived from Lsh+/+ and Lsh2/2 MEFs was treated with
MNase. The DNA was then gel-purified and fragments less than 200 bp were used for real-time PCR. The amplicons were about 10065 bp in size and
were spaced 6065 bp apart. The MNase protected profile of HoxC6(B) and HoxC8(C) genes was determined by normalizing the amount of the MNase
derived PCR products to those of untreated DNA. Error bars represent the mean standard deviation of three to four independent experiments. (D)
MeDIP analysis to enrich for methylated DNA at HoxC6 (left) and HoxC8 (right) genes of Lsh+/+ and Lsh2/2samples after MNase treatment.
doi:10.1371/journal.pone.0009163.g002
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efficient splicing (Fig. 5D). In contrast, WT samples showed a 3 to
8 fold higher ratio in relation to Lsh2/2 when either total
transcripts to mature mRNA (a/c) or pre-mRNA to spliced
mRNA (b/c) were compared. Therefore, the data suggests that
WT samples compared to Lsh2/2 samples are impaired in
converting HoxC6 and HoxC8 pre-mRNA templates into mature
transcripts. To further support the notion that Chd1 is involved in
splicing in Lsh2/2 cells, we examined Chd1 depleted Lsh2/2
cells (as shown in Fig. 4G). Upon Chd1 depletion, the ratio of pre-
mRNA to spliced transcripts reverted back to ratios similar to
those in WT samples pointing to a functional role for Chd1 in
splicing in (Fig. 5E). Taken together, the data suggests an
inadequacy in transcriptional elongation and generation of spliced
mature RNA in WT cells, and successful elongation and splicing of
pre-mRNA in Lsh2/2 cells that involves Chd1.
To address the question, whether changes in DNA methylation
by other means than Lsh depletion can affect Pol II stalling, we
treated WT MEFs with 5-Azacytidine. Bisulphite sequencing
indicated reduced CpG methylation at the TSS region (region1)
and further downstream at the second exon comprising the
splicing signal (region2) after 5-Azacytidine treatment (Fig. 6A and
Fig. S7). Also, hypomethylated WT cells showed re-activation of
repressed HoxC6 and HoxC8 transcripts (Fig. 6B). Moreover, the
Pol II stalling index changed 3 to 4 fold at HoxC6 and HoxC8
genes after 5-Azacytidine treatment (Fig. 6C). In addition, ChIPs
Figure 3. Stalling of RNA polymerase II at Hox genes. (A) Enrichment of unphosphorylated Pol II at HoxC6 (top) and HoxC8 (bottom) genes
using ChIPs. Primers for upstream and downstream regions were positioned within 1000 bp of TSS (five primer sets for each group). TSS primers (two
primer sets) covered the promoter-proximal region. The enrichment of unphosphorylated RNA Pol II (8WG16) binding in Lsh+/+ and Lsh2/2 MEFs
was determined and normalized for better comparison to the binding at TSS in Lsh+/+ (the value of the TSS region was set to 1). (B) Binding of Ser 5
Pol II (H14) using ChIPs at HoxC6 (top), and HoxC8 (bottom) at upstream, downstream regions and the TSS region as in (A). (C) Ratios of Ser 5 Pol II
ChIP signals for the TSS region to the downstream region and the ratios of Ser 5 Pol II signal using a primer set located 59 and 39 of exon1. Error bars
represent the standard deviation for the mean of three independent experiments. (D,E) Binding of Ser 5 Pol II (H14) at HoxC6 (D), and HoxC8 (E) at
upstream, downstream regions and the TSS region in hindlimb (top) and liver tissues (bottom).
doi:10.1371/journal.pone.0009163.g003
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HoxC8 genes after 5-Azacytidine treatment, similar to enhanced
Chd1 binding observed in Lsh2/2samples (Fig. 6D). Finally, the
ratio of total RNA to spliced transcripts (a/c) and pre-mRNA to
spliced transcripts (b/c) were reduced after treatment of WT cells
with 5-Azacytidine suggesting an improved conversion of pre-
mRNA into mature transcripts similar to that seen in Lsh2/2
samples (Fig. 6E). Taken together, the data suggested that
5-Azacytidine treatment can overcame Pol II stalling in WT cells.
To understand whether dynamic regulation of DNA methylation
in MEFs can cause Pol II stalling in hypomethylated Lsh2/2 cells,
we attempted to restore Lsh function. Lsh was introduced into
Lsh2/2MEFs using an inducible tetracycline dependentexpression
system. As shown in Fig. 7A, Lsh protein levels were enhanced
within 24 hrs of tetracycline treatment. Also, HoxC6 and HoxC8
mRNAexpression wasreduced after Lsh induction,asdemonstrated
by RT-PCR analysis (Fig. 7B). This change in gene expression was
accompanied by some gain in CpG methylation at the TSS regions
of HoxC6 and HoxC8 genes (from 11 to 35% at HoxC6 and from 8
to 47%for HoxC8)and at the second exon next to the splicing signal
(Fig.7CandFig.S8A,B).Thisresultwasconsistentwithourprevious
observations that Lsh can directly associate with Hox genes (Fig. S1)
and that Lsh is required for targeting of Dnmt3b to HoxA genes
[16]. Moreover, Lsh re-expression in Lsh2/2 cells increased the Pol
II stalling index (Fig. 7D), further supporting a close connection of
Lsh mediated DNA methylation and Pol II stalling.
To demonstrate that restoration of Pol II stalling does require
Dnmt3b we performed Dnmt3b depletion (Fig. 7E,F) by siRNA
interference in Lsh2/2 cells that expressed tetracycline inducible
Lsh. As shown in Fig. 7G, only control siRNA treated
Lsh2/2cells showed HoxC6 and HoxC8 gene suppression after
Lsh induction, whereas Dnmt3b depleted cells failed to do so.
Bisulphite sequencing and methylation sensitive PCR analysis
indicated increased CpG methylation after Lsh induction when
Dnmt3b was present, but not in Dnmt3b depleted cells (Fig. 7H
and Fig. S9 Fig. S10). This suggests that Dnmt3b plays a role in
Lsh mediated DNA methylation at those sites. In addition, only
control siRNA treated Lsh2/2 cells showed a shift in the ratio of
pre-mRNA to spliced transcripts towards the WT phenotype after
tetracycline induced Lsh expression, but not the Dnmt3b depleted
Lsh2/2 cells (Fig. 7I). Thus, Lsh function is not simply
‘associated’ with DNA methylation levels, but does indeed require
Dnmt3b to mediate gene silencing and Pol II stalling at Hox genes.
Finally, we examined the role of catalytically active Dnmt3b in
HoxC6 and HoxC8 gene silencing. We transfected WT MEFs
with a mutant form of Dnmt3b (a kind gift of Dr Hsieh) that had
been previously shown to be catalytically inactive [45]. RT-PCR
analysis showed an increase in HoxC6 and HoxC8 mRNA in WT
cells that had been transfected with mutant Dnmt3b, in contrast to
control WT cells (mock transfected or transfected with wild type
Dnmt3b) (Fig. 8A). Bisulphite sequencing indicated effective
reduction of CpG methylation at HoxC6 and HoxC8 TSS regions
after introduction of mutant Dnmt3b (Fig. 8B). Calculation of the
Pol II stalling index showed that transfection of mutant Dnmt3b
reduced Pol II stalling in WT cells at HoxC6 and HoxC8
genes (Fig. 8C). Furthermore, the ratio of pre-mRNA to spliced
Figure 4. Chromatin marks associated with transcriptional elongation are increased in the absence of Lsh. (A) Schematic diagram
depicting the position of the primer pairs (black lines) used for ChIP analysis. Comparison of the ratio of H3K36Me3 (B), H3K79Me2 (C) and H3K4Me3
(E) enrichment to total H3 occupancies (Fig. S6) between Lsh WT and Lsh2/2MEFs at up, TSS, down and 39UTR regions of HoxC6 and HoxC8 genes.
(D) ChIP analysis for the detection of Ser 2 RNA Pol II (H5). (F) ChIP analysis for detection of Chd1. (G) Western analysis for detection of Chd1 protein
comparing whole cell extracts derived from Lsh2/2MEFs targeted by Chd1 siRNA or control siRNA (H) Real-time RT-PCR analysis detecting HoxC6
and HoxC8 mRNA in Lsh2/2 MEFs after targeting by Chd1 siRNA compared to control treated cells. Results represent standard deviations for the
mean of three independent experiments. Asterix indicates a p value p,0.05.
doi:10.1371/journal.pone.0009163.g004
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by Lsh2/2 deletion (Fig. 8D). Taken together, the data suggests
that catalytically active Dnmt3b is functionally involved in Pol II
stalling at HoxC6 and HoxC8 genes.
Discussion
Nucleosomal occupancy and DNA methylation at Hox
genes
DNA methylation is a stable epigenetic mark that is generally
associated with repressed, compact and less ‘accessible’ chromatin.
Several studies that assessed nucleosomal distribution identified
some genomic sites that were influenced by DNA methylation as
well as sites that were unaffacted (reviewed in [46]). The effect of
DNA methylation was enhancing as well as preventing nucleoso-
mal occupancy (for example at the chicken beta globin locus)
making it necessary to examine nucleosomal position at the
individual promoter level [8,46]. In the current study we found no
evidence by MNase profiling that the level of DNA methylation
(Fig. 1,2) influences the position of nucleosomes at HoxC6 and
HoxC8 genes. While our MNase assay may be limited to
determine subtle changes (less than 60 bp) in nucleosomal
positioning, the comparable binding pattern of Pol II at TSS in
WT and Lsh2/2 samples further supports the notion of a similar
nucleosomal organization that is independent of DNA methylation
levels. As pointed out above, other genomic sites, for example the
human bidirectional MLH1 promoter, shows nucleosome depo-
sition in the context of DNA methylation, and loss of nucleosomal
occupancy after Azacytidine treatment [8]. The specific DNA
sequence, the relative degree and the precise pattern of CpG
methylation, and the different cell types (human cancer cell versus
MEF) may all affect the outcome. Also, the position of the CpG
island may be important since an in vitro system demonstrated
that CpG island sequences itself could have a destabilizing effect
on nucleosome positioning analogue to the role of AT rich
sequences in S cerevisiae [47]. Based on the many suggested
molecular mechanisms, it is difficult to predict nucleosomal
positioning, and it is therefore advisable to examine individual
methylated promoter regions. Our study indicates in principle that
DNA methylation at CpG islands can be compatible with
accessibility and does not inevitably exclude Pol II engagement.
Pol II stalling versus elongation
We identified here the mechanism of gene silencing, and found in
‘methylated’ WT cells Pol II stalling and in hypomethylated cells all
the hallmarks of transcriptional elongation, including histone
modifications and Ser2 Pol II transition and effective splicing. Pol
II stalling was originally demonstrated to control the expression of
heat shock genes and a number of proto-oncogenes, but recent
reports suggest widespreadregulationof Pol II elongation, including
developmentally regulated Hox genes [28,34,36]. A genome wide
study in human cells found Pol II promoter stalling in embryonic
stem cells as well as somatic B cells and hepatocytes [35]. In murine
macrophages, LPS inducible genes are in part regulated by
transition of the pre-associated Ser5 phosphorylated Pol II into
the elongation phase [48]. In addition, unstimulated genes showed
low levels of pre-mRNA that were quickly degraded. After
stimulation, Ser2 Pol II transition and full length mature transcripts
were deteceted indicating that splicing was effectively regulated
[48]. As for transcriptional regulation of Hox genes we provide
evidence that Chd1 is involved, a chromodomain protein that
associates with elongation as well as splicing factors. The inverse
relationship of DNA methylation and H3K4me3 may serve as
recruitment signal for Chd1 that recognizes directly the tri-
methylation mark. Chd1 can bridge H3K4me3 with FACT or
PAF that are engaged in transcriptional elongation [41,42]. In
Figure 5. Enhanced transcriptional elongation and generation of spliced mature transcripts after Lsh depletion. (A) Schematic
representation of the probe and primer pairs used to detect 59 primary transcripts, unspliced transcripts and spliced mRNA. (B) Real time RT-PCR
analysis detecting the ratio of unspliced to spliced mRNA of the HoxC6 and HoxC8 gene from Lsh+/+ and Lsh2/2 MEFs. Results represent the mean
and standard deviations of three independent experiments. (C) RT-PCR analysis for detection of HoxC6 and HoxC8 transcripts derived from nuclei of
Lsh+/+ and Lsh2/2 MEFs. U2 small nuclear RNA (snRNA) was unaffected by Lsh and served as a control. (D) Real-time RT-PCR analysis from four
independent experiments to detect the ratio of unspliced to spliced nascent transcripts of HoxC6 and HoxC8 genes by nuclear run on assay. (E) Real
time RT-PCR analyses detecting the ratio of unspliced to spliced mRNA of the HoxC6 and HoxC8 genes in Lsh2/2 MEFs after Chd1 siRNA treatment.
Error bars represent the standard deviations for the mean of three independent experiments.
doi:10.1371/journal.pone.0009163.g005
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(U2 snRNP subunits) [42]. Consequently, depletion of H3K4me
levels (using siRNA interference of the HMT Ash2) results in
reduced association of Chd1 to specific chromatin targets and a
decrease in the recruitment of splicing components (SF3A1 and
SF3A2) to selected genomic sites. Furthermore, depletion of splicing
factors such as SC35 reduces transcriptional elongation suggesting a
close relationship between elongation and splicing [44].
Figure 6. 5-Azacytidine treatment overcomes Pol II stalling. (A) Summary of bisulphite sequencing results derived from ten clones (Figure S8)
to illustrate the percentage of reduced CpG methylation after 5-Azacytidine treatment at the first 10 (HoxC6, Up) or 11 (HoxC8, Down) CpG sites
downstream of TSS (region 1) or 10 (HoxC6) or 12 (HoxC8) CpG sites at the second exon (region 2) (B) Real-time PCR analysis for detection of HoxC6
and HoxC8 genes in Lsh+/+ MEFs before and after five days of 5-Azacytidine (Aza) treatment (1 mM). The mock treated samples were set to one for
better comparison. (C) Ratio of Ser 5 Pol II ChIP signals of the TSS region over the downstream region and the ratio of 59r and 39regions of exon1
comparing chromatin derived from Lsh +/+ MEFs of mock and 5-Azacytidine treated cells. (D) ChIPs analysis for detection of Chd1 in the TSS region
comparing chromatin derived from WT MEFs of mock and 5-Azacytidine treated cells. IgG serves as a negative control. (E) Real time RT-PCR analyses
detecting the ratio of unspliced to spliced mRNA of the HoxC6 and HoxC8 gene from Lsh+/+ and Lsh2/2 MEFs after the treatment of 5-Azacytidine.
doi:10.1371/journal.pone.0009163.g006
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We describe here that Pol II promoter stalling at HoxC6 and
HoxC8 genes in WT cells depends on Lsh and is tightly associated
with DNA methylation. There are multiple lines of evidence for a
functional role of DNA methylation beyond the observation of Pol
II stalling in WT cells and elongation in hypomethylated Lsh2/2
cells 1. Lsh and Dnmt3b bind directly to Hox genes and Lsh
regulates Dnmt3b binding [16]. 2. Dynamic regulation of DNA
methylation in WT cells by 5-Azacytine treatment or modulating
Dnmt3b activity overcomes Pol II stalling 3. Likewise, restoration
Figure 7. Re-introduction of Lsh into Lsh2/2 cells restores Pol II stalling and requires the presence of Dnmt3b. (A) Western analysis
using anti-Lsh antibodies or anti-Flag antibodies to detect Lsh protein expression in Lsh2/2 MEFs stably transfected with the tet-off repressor Lsh
vector before and after 24 hrs of tetracycline treatment. Note, that traces of Lsh protein were visible after longer exposure of the blot indicating a
slight leakiness of the repressor system. (B) RT-PCR analysis for detection of HoxC6 and HoxC8 and Lsh mRNA comparing extracts derived from Lsh2/
2MEFs before and after 24 hours of tetracycline treatment. (C) Genomic DNA derived from Lsh2/2 MEFs (before and after 24 hrs of tetracycline
treatment) was examined by bisulphite sequencing at regions downstream of TSS at the HoxC6 (Left) and the HoxC8 (Right) genes. (D) Ratio of Ser 5
Pol II ChIP signals for the TSS region to the downstream region and the ratio of Ser 5 Pol II signal using a primer set located 59 and 39 of exon1
comparing chromatin derived from Lsh2/2 MEFs before and after 24 hours of tetracycline treatment to induce Lsh. Error bars represented the
standard errors of the mean of three independent experiments. Western Blot (E) and Real-time RT-PCR analysis (F) for detection of Dnmt3b mRNA
from Lsh inducible cells treated with control siRNA (siControl) or siRNA targeted against Dnmt3b (siDnmt3b) for 48 hrs. (G) Real time RT-PCR analyses
detecting the ratio of unspliced to spliced mRNA of the HoxC6 and HoxC8 gene in Lsh2/2 MEFs after targeting by Dnmt3b siRNA or control siRNA
before and after 24 hours of tetracycline treatment to induce Lsh. (H) Summary of bisulphite sequencing results derived from ten clones for each
sample (Figure S10) to illustrate the percentage of CpG methylation loss at the first 10 (HoxC6, left) or 10 (HoxC8, right) CpG sites downstream of TSS
in Lsh2/2 MEFs after targeting by Dnmt3b siRNA or control siRNA before and after 24 hours of tetracycline treatment to induce Lsh. (I) Real time RT-
PCR analyses detecting the ratio of unspliced to spliced mRNA of the HoxC6 and HoxC8 genes in Lsh2/2 MEFs after targeting by Dnmt3b siRNA or
control siRNA before and after 24 hours of tetracycline treatment to induce Lsh.
doi:10.1371/journal.pone.0009163.g007
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restores Pol II stalling. 4. Restoration by Lsh requires the presence
of Dnmt3b 5. Pol II stalling requires the catalytic site of Dnmt3b
and thus requires DNA methylation. Though Pol II stalling at the
HoxC6 and HoxC8 genes involves DNA methylation, clearly not
all Pol II stalling is attributed to DNA methylation and Pol II
stalling is found at unmethylated promoter regions [2]. For Hox
genes there may be multiple levels of control of how DNA
methylation contributes to Pol II stalling: for example, a site
specific increase of H3K4me3 may follow reduced DNA
methylation [6,27,43,49,50] and the level of subsequent Chd1
recruitment may influence elongation and splicing. Also, DNA
Figure 8. The catalytic domain of Dnmt3b is required for Pol II stalling. (A) RT-PCR analysis for the detection of HoxC6 and HoxC8 mRNA
from Lsh+/+ and Lsh2/2 MEFs transfected with wild type Dnmt3b (Wt 3b) and Mutant Dnmt3b (Mut 3b) for 72 hrs. (B) Bisulphite sequencing results
to illustrate reduced CpG methylation at the first 10 (HoxC6, Left) or (HoxC8, Right) in samples prepared from WT MEF cells transfected with Mut 3b
for 72 hrs. (C) Ratio of Ser 5 Pol II ChIP signals for the TSS region over the downstream region and the ratio of Ser 5 Pol II signal using a primer set
located 59 and 39 of exon1 comparing chromatin from WT MEFs after the transfection with Mut 3b. (D) Real time RT-PCR analysis detecting the ratio
of unspliced to spliced mRNA of the HoxC6 (left) and HoxC8 (right) gene in WT MEFs after the transfection with Mut 3b.
doi:10.1371/journal.pone.0009163.g008
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protein binding and their subsequent histone modifications
[16,23]. The silencing effect of polycomb proteins has been linked
to altered chromatin environment and Pol II stalling and, recently,
it was proposed that a steric hindrance excluding Pol II elongation
may mediate polycomb silencing [28]. Whether methylated CpG
island genes, other than at HoxC6 and HoxC8 genes, can also
show Pol II stalling requires further investigation. In particular, the
position of CpG sites (upstream, around or downstream of TSS)
deserves further attention since it had been shown that DNA
methylation downstream of TSS can impact transcriptional
elongation at integrated transgenes or episomal plasmids [5,6]. A
recent genome wide DNA methylation analysis observed a strong
association of methylation peaks with the translational initiation
codon [51]. Furthermore, a lack of DNA methylation peaks at
translational initiation codons correlated well with Pol II
elongation efficiency, consistent with the idea that DNA
methylation can regulate Pol II elongation.
Lastly, aberrant DNA methylation patterns at tumor suppressor
genes and at Hox genes have been found in cancer cells, but the
mechanism of transcriptional silencing for many sites remains
uncertain [16,24,26,52,53,54,55]. Our study provides evidence
that DNA methylation at some TSS can be compatible with Pol II
binding. Therefore Pol II stalling may serve as an alternate
mechanism for gene silencing at some methylated tumor
suppressor genes and may suggest the possibility of novel strategies
to interfere with gene silencing in cancer cells.
Materials and Methods
Cell culture, tissues, plasmids and siRNA
The mouse embryonic fibroblasts (MEF) [56] were treated with
1 mM 5-Azacytidine (Sigma) for 5 days. Embryonic tissues were
derived from embryos of day13.5 of gestation. Dnmt3b plasmids
Wt3b (pMT3b) and Mut3b (pMt3bMut, that contains a single
point mutation at position 657 converting cysteine to serine
resulting in catalytically inactive enzyme) [45] were a kind gift
from Dr. Hsieh (University of Southern California) The pT-REx-
Lsh plasmid was constructed by subcloning Flag-tagged Lsh [57]
into the pcDNA4/TO vector (Invitrogen). Lsh2/2 MEFs were
transfected with pcDNA6/TR (Invitrogen) and pT-Tex-Lsh and
stable clones were selected with 300 mg/ml Zeocin and 10 mg/ml
Blasticidin. Lsh protein was induced by adding 6 mg/ml
tetracycline. For si RNA interference cells were transfected with
Dnmt3b, Chd1siRNA or control siRNA (Dharmacon) using
Dhamafect Duo Transfection Reagent.
Western analysis and antibodies
Equal amounts of protein (20,50 mg) were separated on 4–12%
Bis-Tris SDS-PAGE (Invitrogen) and transferred onto a nitrocel-
lulose membrane. The following antibodies were used: normal
mouse or rabbit IgG (Upstate), rabbit anti-Lsh recombinant protein
affinity-purified antibody [16]; 8WG16 Pol II (ab817), H14 Pol II
(ab24759), H5 Pol II (ab24758, anti-H3 (ab1791), anti-H3 (di
methyl K79) (ab3594), anti-H3 (tri methyl K36) (ab9050), anti-H3
(tri methyl K4) (ab8580) (Abcam); 5-Methylcytidine (BI-MECY-
0100)(Eurogentec); anti-Flag (F1804), anti-b-actin (A2228), anti-
Brdu (B2531)(Sigma); anti-Dnmt3b (ALX-804-233-C100)(Alexis
Biochemicals); anti-CHD1 (NB100-60411) (Novus Biologicals Inc).
PCR analysis
For RT-PCR analysis total RNA was extracted using Qiagen
RNeasy Mini Kit and 2 mg were reverse transcribed with 50 ng
random primers and 10U Reverse Transcriptase (Superscript III
Kit, Invitrogen). The cDNA was diluted 1:10, and 2 ml were used
for analysis. Results were normalized for expression of the
housekeeping gene Gapdh. For methylation-sensitive PCR
analysis [58] DNA was extracted by using Qiagen DNeasy kit
and 1.0 mg was digested with Mae II (Roche) or BssH I (NEB).
PCR analysis was carried out as follows: 3 min at 94uC, 35 cycles
of 30 s at 94uC, 30 s at 55uC, and 30 s at 72uC, and finally 5 min
at 72uC. For Real-time PCR analsysi as described by [16] a
standard curve was generated by serially diluting input samples.
For MNase digestion the fold difference was calculated [59]
between MNase-treated and untreated samples. Values used were
collected from the linear range of amplification. Primers are listed
in the supplemental Table S1.
MNase protection analysis
The assay was carried out as descriped previously [60]. In brief,
after lysis of single cell suspensions, chromatin was digested with
MNase, DNA extracted by phenol:chloroform and separated on a
1.5% agarose gel. This procedure yielded ,80% DNA from
mononucleosome (,150 bp) and ,20% DNA from di- and
trinucleosomes (,300 and ,450 bp, respectively). The mono-
nucleosomal DNA was excised, gel-purified, and used as a PCR
template.
ChIP and MeDIP analysis
ChIPs were performed as previosuly described (Xi et al., 2007).
Sonication yielded fragments between 300 to 500 bp in average.
For detection of H3 modifications data was normalized by
performing simultaneously ChIP analysis using anti-H3 antibod-
ies. Before carrying out MeDIP, genomic DNA was digested with
Mse I or/and Pst I to produce random fragments ranging in size
from 200 to 500 bp. Onemg of gel purified DNA was used for a
MeDIP assay as described previously [2]. Real-time PCR analysis
was performed, for each primer the amplication efficiency was
calculated and the data expressed as enrichment related to Input.
Bisulphite sequencing
Genomic DNA (1 mg) was subjected to bisulphite treatment by
using MethylDetector Bisulphite Modification kit (Active Motif).
Amplified fragments were subcloned into the pCR2.1-TOPO
vector (Invitrogen). Independent clones were sequenced by using
the M13 F primer and only sequences with individual fingerprint
selected for analysis.
Nuclear run-on assays
Nuclear RNA was extracted from the nuclei using RNeasy mini
kit (Qiagen). The nuclear run-on assay has been previously
described [44]. In brief, a NTP mix plus BrUTP was used wheras
the control reactions for monitoring nonspecific binding omitted
NTPs. The run-on reaction was performed at 25uC for 15 min on
about 10
7 permeabilized cells and DNase I–treated total RNA was
extracted and immnuprecipitated using anti-BrU antibody
(B2531, Sigma) andml Protein G Dynabeads (Invitrogen). Recov-
ered RNA was reverse transcribed and analyzed by Real-time
PCR.
Supporting Information
Figure S1 Lsh association with Hox genes. ChIP analysis using
specific antibodies against Lsh (or control IgG) followed by PCR
analysis to detect association of Lsh with promoter regions, TSS,
and gene body regions of HoxC6 (A), HoxC8 (B) and HoxA6 (C)
genes comparing Lsh+/+ and Lsh2/2 MEFs. Enrichment is
represented as a percentage of input. Error bars represent
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experiments.
Found at: doi:10.1371/journal.pone.0009163.s001 (0.50 MB TIF)
Figure S2 DNA methylation analysis at HoxC6 and HoxC8
genes. (A,B) Methylation sensitive PCR to determine DNA
methylation level at HoxC6 (A) and HoxC8 (B) genes. The map
on top illustrates the position of methylation-sensitive restriction
enzyme (Mae II), as well as the primers used for the methylation-
sensitive PCR analysis (Top). PCR analysis using genomic DNA
derived from Lsh+/+ and Lsh2/2 MEFs after digestion with
Mae II. The undigested DNA served as a control for equal input of
DNA (Uncut). (C,D) MeDIP analysis for detection of CpG
methylation at the HoxC6 (C) or HoxC8 (D) genes. Region 1
(devoid of CpG sites) was amplified as negative control. Genomic
DNA was digested with Mse I (C) or Mse I and Pst I (D),
immunoprecipitated with anti-5-methylcytosine antibodies and
specific Hox locations assessed by real-time PCR. Binding was
expressed as a percentage of the input DNA. The bar graphs
represent the mean of two independent MeDIP experiments.
Found at: doi:10.1371/journal.pone.0009163.s002 (0.39 MB TIF)
Figure S3 MNase protection profile at HoxA6. (A) The MNase
protected profile of HoxA6 was determined by normalizing the
amount of the MNase derived PCR products to those of the
untreated DNA. (B) Enrichment of unphosphorylated Pol II (left)
and Ser 5 Pol II (right) at HoxA6. (C) Ratio of Ser 5 Pol II ChIP
signals at the TSS region over the downstream region of HoxA6
and the ratio of Ser 5 Pol II signal using a primer set located within
exon1.
Found at: doi:10.1371/journal.pone.0009163.s003 (0.43 MB TIF)
Figure S4 Identification of major transcriptional start sites (TSS)
at HoxC6 and HoxC8 genes. (A). Identification of HoxC6 TSS
using cDNA derived from Lsh2/2 MEFs and primer specific for
TSS region 1 and region 2. RT-PCR analysis suggest that regions
2 (as marked in Fig. 1 and Fig. 2 as TSS) is indeed the major
TSS for HoxC6 since no signal was detected fro region 1.
(B) Identification of HoxC8 TSS using cDNA derived from
Lsh2/2 MEFs and primer specific for TSS region 1. (C,D)
Identification of HoxC6 (C) and HoxC8 (D) TSS using RLM-
RACE. RNA is treated with tobacco acid pyrophosphatase (TAP)
to remove the cap structure from the full-length mRNA leaving a
59-monophosphate which is subsequently ligated to a synthetic
RNA adaptor. After reverse transcription nested gene specific
primers and adaptor specific primers are used for gene specific
amplification. Results indicate a major amplification product
about 320 bp for HoxC6 and 290 bp for HoxC8 confirming the
preferential use of the predicted TSS for both genes. The major
TSSs are reported in the Mouse Genome database (MGI) at
chr15:102,839,993 for HoxC6 and at chr15:102,820,970 for
HoxC8.
Found at: doi:10.1371/journal.pone.0009163.s004 (0.63 MB TIF)
Figure S5 Protein analysis in the absence of Lsh. (A) Western
analysis of extracts derived from Lsh+/+ and Lsh2/2 MEFs
using the indicated antibodies. (B) Real-time RT-PCR analysis for
detection of Chd1 mRNA from Lsh2/2 MEFs treated with
control siRNA (siControl) or siRNA targeted against Chd1
(siChd1) for 48 hrs.
Found at: doi:10.1371/journal.pone.0009163.s005 (0.46 MB TIF)
Figure S6 Nuclear run on assay. (A) Schematic diagram for the
nuclear run-on assay based on the use of BrUTP. The nascent
transcript snRNA detection was demonstrated by analyzing total
RNA from Lsh+/+ and Lsh2/2 MEFs labeled with BrU, Uridine
(U) and BrU in the presence of a-amanitin. (B) PCR products with
reverse transcriptase (+RT) or without reverse transcriptase (-RT)
from nascent RNA that were immunoprecipitated by anti-Br-UTP
antibody for detection of nascent RNA generated in the nuclear
run on assay. The WT sample generated with RT served as
positive control. Data indicate the purity of the nascent RNA used
for the assay.
Found at: doi:10.1371/journal.pone.0009163.s006 (0.43 MB TIF)
Figure S7 DNA hypomethylation after 5-Azacytidine treatment.
Genomic DNA derived from Lsh+/+ MEFs before and after
treatment of 5-Azacytidine was examined by bisulphite sequencing
at region 1 (top) and region 2 (2nd exon, bottom) at the HoxC6 (A)
and the HoxC8 (B) genes.
Found at: doi:10.1371/journal.pone.0009163.s007 (0.72 MB TIF)
Figure S8 Re-introduction of Lsh in Lsh2/2 MEFs. Genomic
DNA derived from Lsh+/+ and Lsh2/2 MEFs before and after
24 hours of tetracycline treatment to induce Lsh was examined by
bisulphite sequencing at regions of the second exon at the HoxC6
(A) or HoxC8 (B) genes. Methylated CpGs are presented by black
circles and unmethylated sites by open circles.
Found at: doi:10.1371/journal.pone.0009163.s008 (0.74 MB TIF)
Figure S9 DNA hypomethylation after Dnmt3b depletion.
Methylation sensitive PCR to determine methylation level at
HoxC6 (A) and HoxC8 (B) after targeting by Dnmt3b siRNA or
control siRNA before and after 24 hours of tetracycline treatment
to induce Lsh in Lsh2/2 cells. The map on top illustrates the
position of methylation-sensitive restriction enzyme (Mae II in
HoxC6 and BssH II), as well as the primers used for methylation-
sensitive PCR analysis (Top). PCR analysis using genomic DNA
derived from Lsh2/2 MEFs after digestion with Mae II and BssH
II. The digested DNA without enzyme sites served as a control for
equal input of DNA (Bottom).
Found at: doi:10.1371/journal.pone.0009163.s009 (0.11 MB TIF)
Figure S10 Dnmt3b is required for re-methylation at HoxC6
and HoxC8. Genomic DNA derived from Lsh2/2 MEFs after
targeting by Dnmt3b siRNA or control siRNA before and after
24 hours of tetracycline treatment to induce Lsh. HoxC6 (A) and
the HoxC8 (B) genes were examined by bisulphite sequencing.
Methylated CpGs are presented by black circles and unmethylated
sites by open circles.
Found at: doi:10.1371/journal.pone.0009163.s010 (1.39 MB TIF)
Table S1 Primers for PCR, ChIP, Nuclear Run on and real-
time PCR
Found at: doi:10.1371/journal.pone.0009163.s011 (0.16 MB
DOC)
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